It is reported that Stemedica, the company backed by the M&A fund in which Jiuzhi堂 has invested, has received approval from Kazakhstan’s Ministry of Health for its therapy utilizing human bone marrow mesenchymal stem cells produced by Stemedica to treat acute myocardial infarction. Meanwhile, Jiuzhitang Maker, also part of the M&A fund, has jointly established the "Jiuzhi堂-ALTACO Stem Cell International Medical Center" with ALTACO-XXI on the Kazakh side of the Khorgos China-Kazakhstan Free Trade Zone. ALTACO-XXI holds an exclusive cell-supply agreement with Stemedica and will oversee the center’s daily operations and medical management, with support from Meike. According to the collaboration agreement, any patient holding a Chinese passport (including those from Hong Kong, Macau, and Taiwan) seeking treatment at the medical center must first be referred by Jiuzhitang Maker. This marks another significant step forward for Jiuzhitang Maker’s stem cell business, following the establishment of a joint research facility with Beijing Tiantan Hospital to advance preclinical studies on stem cells.

Traditional Chinese medicine company Jiuzhitang has also been impacted by policy changes. Facing these challenges, Jiuzhitang hasn’t backed down. While strengthening its core traditional business and continuing to demonstrate the remarkable efficacy of its flagship product, Shuxuetong, the company is actively expanding into emerging fields such as stem cells and diabetes—areas with significant growth potential. Jiuzhitang is committed to transforming itself into a leading, innovative brand that seamlessly blends traditional and cutting-edge approaches, helping people not only prevent illness but also effectively treat it.

The phrase "Challenges are also opportunities" perfectly encapsulates the spirit of Jiuzhitang, whose core value—“A Century of Jiuzhitang, Dedicated to Greater Health”—is driving a proactive shift from marketing-driven to innovation-led growth. While diligently safeguarding the market foundation of its flagship products, the company is actively exploring and developing new offerings and cultivating emerging growth areas. It’s also venturing into the healthcare service ecosystem and the broader health industry, steadily advancing initiatives like group-based management and goal-oriented strategies—key pillars that ensure the company’s stable and sustainable development. Notably, Jiuzhitang has already achieved significant milestones in the cutting-edge field of stem cells, providing a powerful boost to the company’s long-term viability and growth.

Stem cells are living medicines—and they are medicines that serve humanity itself. Modern medicine often finds itself powerless against many complex and challenging diseases, placing its hopes squarely on stem-cell therapies, whose promising future is beyond doubt. According to data from the Qianzhan Industry Research Institute, the global stem-cell industry continues to expand rapidly: in 2018, the global market for stem cells surpassed $100 billion, reaching $119.5 billion, with projections indicating it will grow further to $174.5 billion by 2020.

It is reported that Stemedica, the company under the M&A fund in which Jiuzhi堂 has invested, has received approval from Kazakhstan’s Ministry of Health for its therapy using Stemedica-produced human bone marrow mesenchymal stem cells to treat acute myocardial infarction. Meanwhile, Jiuzhitang Maker, also part of the M&A fund, has jointly established the "Jiuzhi堂-ALTACO Stem Cell International Medical Center" with ALTACO-XXI on the Kazakh side of the Khorgos China-Kazakhstan Free Trade Zone. ALTACO-XXI holds an exclusive cell-supply agreement with Stemedica and will oversee the center’s daily operations and medical management, with support from Meike. According to the collaboration agreement, any patient holding a Chinese passport (including those from Hong Kong, Macau, and Taiwan) seeking treatment at the medical center must first be referred by Jiuzhitang Maker. This marks another significant step forward for Jiuzhitang Maker’s stem cell business, following the establishment of a joint research facility with Beijing Tiantan Hospital to advance preclinical studies on stem cells.

Nine Flavor Herbal Medicine has been around since 1650, carrying the legacy of a time-honored traditional Chinese medicine brand. Over the years, as times have evolved and industries advanced, it has grown into a robust enterprise with more than 20 subsidiaries and over 300 chain stores nationwide. Beyond its extensive retail network, Nine Flavor Herbal Medicine boasts an impressive portfolio of over 300 approved product registrations spanning key therapeutic areas such as cardiovascular and cerebrovascular health, tonifying and calming remedies, gynecology, respiratory care, digestive wellness, heat-clearing treatments, ENT care, orthopedics, dermatology, and pediatrics. As a nationally recognized leader among China’s key traditional Chinese medicine enterprises, a national high-tech innovation enterprise, and a pilot company for national innovation, Nine Flavor Herbal Medicine also holds a prominent position as the industry leader in Hunan Province’s pharmaceutical sector. With its deep historical roots, strong brand reputation, and significant industry influence, coupled with its strategic focus on advancing in the rapidly growing field of stem cell research, we believe Nine Flavor Herbal Medicine is poised for an exciting and promising future.